Promotional material

Vaccine update: issue 351, October 2024

Published 15 November 2024

Applies to England

We’d like to extend a huge thanks to all the immunisation teams across the country who have been working tirelessly to deliver all the immunisation programmes so far as we prepare for the winter season.  It is brilliant to see that since the launch of the RSV programmes on 1 September, over three-quarters of a million vaccinations have been delivered across England. (844,144 up to 31/10/24, see Vaccinations: RSV). For further details of the RSV programme launch please see Vaccine update: issue 347.

Prenatal pertussis vaccination coverage in England from April to June 2024

This quarterly report evaluates prenatal pertussis vaccine coverage for women who delivered in the April to June 2024 quarter who were eligible for the prenatal pertussis vaccine from 16 weeks of pregnancy onwards.

The main findings were that:

• pertussis vaccine coverage in pregnant women for the first quarter of the 2024 to 2025 financial year (2024/25) was 58.9% in April, 59.0% in May and 60.9% in June
• the mean coverage for the quarter was 59.6%, which was 1.5 percentage points higher than the mean coverage for the same quarter in 2023/24 and was the first quarterly increase in coverage since quarter 4 of 2019/20
• prenatal pertussis vaccine coverage by Integrated Care Board (ICB) ranged from 23.2% (North Central London, June 2024) to 79.8% (Shropshire, Telford and Wrekin, June 2024)
• despite an increase in coverage this quarter, there has been an 8.1.% decline in coverage compared to the peak coverage in the same reporting quarter of 2016/17

UKHSA hosts EUPert scientific meeting

On 2 and 3 October, the UKHSA Immunisation Publications team attended the 24th EUPertStrain-EUPertGenomics meeting (EUPert). EUPert is a European network for pertussis strains and genomics, which looks at improving pertussis surveillance and studying changes to vaccine effectiveness across European countries. This is coordinated by the University of Turku in Finland and involves a range of laboratories and organisations which includes UKHSA.

The meeting was an opportunity to bring together parthers who study and monitor pertussis cases in their jurisdictions, to share information and best practices. The meeting gave valuable insight into changes in epidemiology, with increasing cases across Europe which is similar to what we are experiencing in the UK. Interestingly, across certain countries pertussis subtypes have changed, potentially because of vaccination. This did really drive home the importance of vaccination against pertussis.

This year was UKHSA’s turn to organise EUPert, and the Immunisation Publications team assisted with the logistics and event planning. The meeting took place in the Museum of London Docklands. Initially this proved quite a challenge to find the right sized venue with a reasonable location and cost but ultimately turned out to be the ideal place with the best food and architecture the writer has experienced at a conference so far. The next challenged proved to be finding somewhere to eat after the conference. Thankfully the opportunity presented itself with the ledger building where we could treat our attendees to a ‘traditional pub dinner’. The next question was how to entertain the attendees after a heavy day of scientific content. One of our team had the idea of a boat ride after the conference up the Thames. This went swimmingly (not literally thankfully) and proved a great hit with over 40 delegates embarking at Canary Wharf for a voyage down the Thames to Embankment. All considered this was an excellent conference with some fascinating content. A terrific effort by all the organisers for a fascinating agenda and a well executed event.

Autumn events

The Immunisation Publications team and member of the Nursing and Midwifery team from Immunisation at UKHSA were at both Best Practice on 9 and 10 October at the Birmingham NEC and Nursing Live 23 and 24 October at the Liverpool ACC. Both of these events were fantastic and it was a real privilege to meet so many interested and enthusiastic health professionals from across the country. We gave out a huge amount of immunisation resources and shared details of how to order and utilise our materials for free from the HealthPublications website and ordering system. We also got to have a broad range of discussions about the immunisation programmes and portfolio which is always fascinating. Thank you so much to the event organisers and to all the delegates who dropped by for a chat or to get some stickers and leaflets!

We will be at Pulse 365 and Nursing 365 back in Liverpool at the ACC on November 12 and 13 and at a number of other events before the year is out.

Would you like to appear in Vaccine Update?

As this year draws to a close we would like to once again invite anyone to submit a brief article for vaccine update. Articles should focus on examples of ‘How we did it’, immunisation best practice at any level. Have you been running accessible clinics? Have you trialled home visits in your local area? Do you have a novel model of call-recall? We and our readers would love to hear about it.

Submissions should be between 300 and 500 words, ideally with a photograph. Please get in touch at immunisation.website@ukhsa.gov.uk to submit an article or to discuss a future submission.

Reminder: Shingles programme and Zostavax

The final batch of Zostavax supplied by ImmForm for the national shingles vaccination programme expired on 31 October 2024. Providers should discard any remaining stock that they have in their vaccine fridges.

Shingrix is now the only vaccine available for this programme. Individuals previously eligible for Zostavax and aged up to 79 years of age who have not yet received their shingles vaccine should now instead be offered a 2-dose course of Shingrix. Full details are included in the current Information for Healthcare Practitioners guidance and training slide set.

Shingles the green book chapter 28a (up to 31 August 2023) has now been withdrawn and should no longer be used. Please now refer only to the current Shingles green book chapter 28a (from 1 September 2023). References to Zostavax administration will shortly be removed from the Information for Healthcare Practitioners document and the training slide set.

Changes to the ImmForm Website Address

From 20 November at 17.30, the ImmForm website address will change from a PHE to a UKHSA domain name. Following the change ImmForm must be visited using the new UKHSA domain URL. This is happening because as a UKHSA system, ImmForm must use an appropriate UKHSA domain URL, departing form the legacy PHE domain to remain available to users.

Preparing for this URL change

• users can test to see if they will be able to access ImmForm at the new URL by clicking through to the ImmForm logo and making sure that they can see the red and white logo on the page
• some IT teams responsible for maintaining computer hardware at customer sites impose firewall or other restrictions that can affect a users ability to access sites available on the internet
• users should contact their local IT support desk well ahead of the change to confirm access to any site with the immform.ukhsa.gov.uk URL won’t be blocked. This should include portal.immform.ukhsa.gov.uk, vaccinesupply.immform.ukhsa.gov.uk, assets.immform.ukhsa.gov.uk
• this is especially advised if you are aware of internet restrictions on the computer you use or you cannot see the ImmForm logo using the link above
• update any browser bookmarks to the new UKHSA URL, the old links using the PHE domain will redirect to a holding page with further details and guidance about this change

If you experience any issues accessing ImmForm you can get in touch with the ImmForm helpdesk, available Monday to Friday 09:00 – 17:00 via email on helpdesk@immform.org.uk.

Vaccine supply

Routine vaccination programme

Christmas 2024 and New Year 2025 deliveries

Due to the Christmas and New Year Bank Holidays, there will be no deliveries or order processing by Movianto UK on Wednesday 25 and Thursday 26 December 2024 and on Wednesday 1 January 2025. ImmForm customers should prepare for the break in deliveries and to order accordingly. ImmForm customers with a standard delivery day of Wednesday, please be aware that after Wednesday 18 December 2024, your next delivery day will be Wednesday 8 January 2025.

Exceptions for offshore customers will be published online as an ImmForm news article.

Please ensure you have enough room in your fridge for any additional vaccine that you order in advance of this holiday period, bearing in mind the recommendation that only 2 to 4 weeks of vaccine stock should be held locally.

Please be advised that Emergency or ‘Out of Schedule”’deliveries cannot be arranged for ImmForm customers who fail to place orders in good time.

Standard delivery date	Order cut-off date	Order cut-off time	Notes
Monday 16 December 2024	Thursday 12 December 2024	11.55 AM	N/A
Tuesday 17 December 2024	Friday 13 December 2024	11.55 AM	N/A
Wednesday 18 December 2024	Monday 16 December 2024	11.55 AM	Next Wednesday delivery 8 January
Thursday 19 December 2024	Tuesday 17 December 2024	11.55 AM	Next Thursday delivery 2 January
Friday 20 December	Wednesday 18 December 2024	11.55 AM	N/A
Weekend
Monday 23 December 2024	Thursday 19 December 2024	11.55 AM	N/A
Tuesday 24 December 2024	Friday 20 December	11.55 AM	N/A
Wednesday 25 December 2024	Christmas Day	Closed	No deliveries or order processing
Thursday 26 December 2024	Boxing Day	Closed	No deliveries or order processing
Friday 27 December 2024	Monday 23 December 2024	11.55 AM	N/A
Weekend
Monday 30 December 2024	Tuesday 24 Decemeber 2024	11.55 AM	N/A
Tuesday 31 December 2024	Friday 27 December 2024	11.55 AM	N/A
Wednesday 1 January 2025	New Years Day	Closed	No deliveries or order processing
Thursday 2 January 2025	Monday 30 December 2024	11.55 AM	Scotland orders delivered 3 January
Friday 3 January 2025	Tuesday 31 December 2024	11.55 AM	N/A
Weekend
Monday 6 January 2025	Thursday 2 January 2025	11.55 AM	N/A
Tuesday 7 January 2025	Friday 3 January 2025	11.55 AM	N/A
Wednesday 8 January 2025	Monday 6 January 2025	11.55 AM	N/A
Thursday 9 January 2025	Tuesday 7 January 2025	11.55 AM	N/A

Change of vaccine brand for meningococcal groups A, C, W and Y (MenACWY) vaccination

The vaccine used for meningococcal groups A, C, W and Y (MenACWY) vaccination will change from Nimenrix® to MenQuadfi®. Please continue to order and administer Nimenrix® until ImmForm and local stockholdings deplete.

UKHSA expect to make MenQuadfi® vaccine available to order via ImmForm from Monday 25 November 2024, once Nimenrix® depletes sufficiently. This date remains subject to change and any further updates to ordering information will be published online as an ImmForm news article. High-level ordering controls will be in place to reduce the risk of ordering errors only. These are not intended to restrict activity.

MenQuadfi® vaccine ordered via ImmForm will be supplied as a single-dose pack, containing one vial of vaccine and a Patient Information Leaflet (PIL). The pack does not contain a needle or a syringe for administration. Guidance on the choice of needle size can be found in chapter 4 of the Green Book. Needles and syringes should be obtained locally.

MenQuadfi® and Nimenrix® vaccines are packed in different sized cartons. Please ensure you have enough fridge capacity before placing any orders. To help with planning storage requirements, the dimensions are as follows:

• MenQuadfi® is 58 x 32 x 45mm (H x W x D)
• Nimenrix® was 57 x 27 x 135mm (H x W x D)

Please add MenQuadfi® to your routine ImmForm order where possible, rather than creating additional orders.

To minimise wastage due to fridge failures, please order no more than 2 weeks’ worth of stock.

Details about the meningococcal vaccination programme is published in chapter 22 of the Green Book.

Further details about MenQuadfi® vaccine can be found in the Summary of Product Characteristics (SmPC).

Contact helpdesk@immform.org.uk for ordering queries.

Change of vaccine for the pertussis (whooping cough) vaccination in pregnancy programme from 1 July 2024

From 1 July 2024, the vaccine used for the pertussis (whooping cough) vaccination in pregnancy programme changed from Boostrix-IPV® to ADACEL®. Please refer to the prenatal pertussis vaccine change letter from July 2024.

ADACEL® is now available to order via ImmForm. High-level ordering controls are in place to reduce the risk of ordering errors only. These are not intended to restrict activity. Any further updates to ordering information will be published online as an ImmForm news article.

Boostrix-IPV® continues to be the vaccine used for the pre-school booster vaccination of children, and for the maternal programme if ADACEL® is not available or is otherwise unsuitable (such as in individuals with a severe allergy to latex).

Providers who do not administer pre-school boosters, and were unable to use up locally held stock of Boostrix-IPV® ahead of the change on 1 July 2024, may offer any remaining locally held stock of Boostrix-IPV® to pregnant women if this will prevent vaccine wastage.

ADACEL® vaccine ordered via ImmForm is supplied as a single-dose pack, containing one pre-filled syringe. The pack does not contain a needle for administration. Guidance on the choice of needle size can be found in chapter 4 of the Green Book. Needles should be obtained locally.

Please add ADACEL® to your routine ImmForm order where possible, rather than creating additional orders.

To minimise wastage due to fridge failures, please order no more than 2 weeks’ worth of stock.

Details about the pertussis (whooping cough) vaccination programme is published in chapter 24 of the Green Book.

Further details about ADACEL® vaccine can be found in the SmPC.

Contact helpdesk@immform.org.uk for ordering queries.

Introduction of Abrysvo® RSV vaccine for older adults and during pregnancy for infant protection

From 1 September 2024, RSV (respiratory syncytial virus) programmes were introduced for older adults and during pregnancy for infant protection. Please refer to the letter introducing the new NHS programmes against RSV.

The same RSV vaccine, Abrysvo®, is used for both programmes.

Abrysvo® vaccine is now available to order via ImmForm. Customers in Scotland should refer to local ordering guidance. High-level ordering controls are in place to reduce the risk of ordering errors only. These are not intended to restrict activity. Any further updates to ordering information will be published online as an ImmForm news article.

Abrysvo® vaccine ordered via ImmForm is supplied as a single-dose pack, containing one vial of vaccine, diluent for reconstitution and a PIL.

Each pack also contains one 25G x 25mm (1”) needle. Guidance on the choice of needle size can be found in chapter 4 of the Green Book. If required, other sizes of needles should be obtained locally.

The pack of Abrysvo® vaccine is physically larger than most other vaccines supplied via ImmForm. The vaccine must be stored between 2 to 8˚C. Please ensure you have enough fridge capacity before placing any orders. To help with planning storage requirements, each single dose pack measures 73mm x 35mm x 116mm (H x W x D).

When ordering Abrysvo® vaccine, orders should be placed for the ImmForm product that is specific to each RSV protection programme.

Product ordered for the infant RSV protection programme (offered to pregnant women) should not be used for the older adult RSV protection programme and vice versa. Account holders will see 2 different product lines and should order accordingly.

To minimise wastage due to fridge failures, please order no more than 2 weeks’ worth of stock. 

Details about the RSV vaccination programmes is published in chapter 27a of the Green Book.

Further details about Abrysvo® vaccine can be found in the SmPC.

Contact helpdesk@immform.org.uk for ordering queries.

Vaccines for the 2024 to 2025 children’s flu programme supplied by UKHSA

All flu vaccines for the 2024 to 2025 children’s flu programme are available to order by NHS providers in England via ImmForm.

UKHSA does not supply any flu vaccines for patients aged 18 years and over.

Please refer to guidance from your respective health departments for arrangements in Scotland, Wales and Northern Ireland.

Important update regarding the live attenuated influenza vaccine (LAIV)

From 2024, LAIV will be a trivalent vaccine (rather than a quadrivalent) due to the removal of the B-Yamagata strain. This change in formulation by AstraZeneca was recommended by the World Health Organization and is supported by the JCVI. The brand name for the trivalent vaccine is Fluenz® (the quadrivalent vaccine was named Fluenz® Tetra).

Presentation of the vaccine (that is, pre-filled single-dose nasal spray, supplied in a 10-dose pack) remains the same, and LAIV is available to order via ImmForm for providers of the children’s flu programme as usual.

Vaccines and availability

The 2 vaccines that are available, and the groups that these vaccines should be ordered for, are set out in the table below.

Vaccine	Manufacturer	Available to order for
Fluenz® (LAIV)	AstraZeneca	all children from 2 years of age to school year 11, and children in clinical risk groups aged 2 to <18 years [note 1]
Cell Based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) (QIVc)	Seqirus	children in clinical risk groups aged 6 months to <2 years, and all other eligible [note 2] children aged 2 to <18 years for whom LAIV is unsuitable

Note 1: unless LAIV clinically contraindicated or otherwise unsuitable.

Note 2: children from 2 years of age to school year 11, and children in clinical risk groups aged 2 to <18 years. 

The latest and most accurate information on availability of centrally supplied vaccines for the children’s flu programme is available on the ImmForm news page at all times. It is strongly advised that all parties involved in the provision of influenza vaccines to children ensure they remain up to date with this.

LAIV ordering information for General Practice

Ordering controls are in place for general practices, to enable UKHSA to balance supply with demand. These controls work by allocating an amount of LAIV based on the number of registered eligible patients and are tailored to each practice. GPs are able to place one order and receive one delivery of LAIV per week.

At this time:

• each GP practice has been allocated sufficient LAIV to vaccinate at least 45% of their eligible patients (all 2- and 3-year-olds, plus children in clinical risk groups from age 4 to <18 years)
• increases to these allocations will be made in response to demand and vaccine availability
• requests for extra vaccine will be considered on a case-by-case basis throughout the ordering period. Requests for additional vaccine should be sent to helpdesk@immform.org.uk and should be sent in good time before your order cut-off. Out-of-schedule deliveries will be by exception only

Multi-branch practices and LAIV allocations

Please note that GP practices or groups that operate over multiple sites but are part of the same organisation will have a joint allocation (as in previous years), even where each site has a unique ImmForm account. This means that it is possible for one site to potentially order all of the available vaccine for the group, unless there is local agreement on how the allocated volume is shared. UKHSA recommends that this agreement is in place before ordering commences to reduce the risk of supply interruption. The information above allows practices to estimate the amount of vaccine they will be initially allocated, and how it should be split between all sites.

LAIV ordering information for school-age providers

School providers are able to place 2 orders and receive 2 deliveries of LAIV per week, to assist in the management of vaccine volumes required across limited storage space at delivery points.

This operates on a 48-hour delivery schedule requiring the order to be placed before the 11:55am cut-off 2 working days before the required delivery day. The table below illustrates the respective delivery days versus ordering days.

Please note the bank holiday schedule when placing orders for delivery over the Christmas period

Order day (before 11:55am cut-off)	Delivery day
Monday	Wednesday
Tuesday	Thursday
Wednesday	Friday
Thursday	Monday
Friday	Tuesday

Customers must ensure that the point of delivery will be open and staffed between 9am and 5pm on the delivery day when placing orders. 

Please note that this 48-hour delivery schedule does not affect the routine ordering and delivery schedule of any other vaccines (including inactivated flu vaccines) ordered from ImmForm and is applicable to Fluenz® (LAIV) only.

A default weekly ordering cap of 450 packs (4,500 doses) per week will be in place for school provider accounts.

Where this cap is insufficient and a provider needs a larger weekly volume of vaccine to deliver the programme (for example where a provider covers a large area using a single account), a higher weekly cap should be requested via the UKHSA Flu Vaccine Operations team by emailing childfluvaccine@ukhsa.gov.uk.

For one-off larger orders during the ordering period, requests should be made via helpdesk@immform.org.uk.

Inactivated flu vaccine ordering

The Cell Based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) (QIVc) is available to order, in a single-dose pack, for:

• children in clinical risk groups aged from 6 months to less than 2 years old
• children aged from 2 to <18 years old in clinical risk groups for whom LAIV is clinically contraindicated or otherwise unsuitable
• healthy children from 2 years old to those in school year 11, for whom LAIV is unsuitable (for example, due to objection to LAIV on the grounds of its porcine gelatine content)

Order controls are also in place for this vaccine as follows:

• for GPs, there is a cap of 10 doses/packs per week
• for school-age providers, there is a cap of 450 doses/packs per week

All influenza vaccines for the 2024 to 2025 season

Information on all influenza vaccines that have been marketed in the UK for the 2024 to 2025 season is available here.

The impact of changes to opening hours on routine vaccine deliveries

Please consider temporary changes to opening times when placing ImmForm orders. If you are aware of a scheduled site closure, please refrain from placing an order for that date. In case of a one-off closure, consider rescheduling your order for the week before or after. This approach will contribute to improved overall efficiencies and enhance delivery performance for the benefit of all customers.

It is not possible to accommodate one-off changes to delivery days. Customers should report long-term changes to the days and times when they can accept deliveries, such as routine training days and closures, by contacting Movianto UK Customer Care via email at moviantouk.nhscc@movianto.com or by phoning 01234 587 207. This should not be used to report short-term changes due to absence or holidays.

DTaP/IPV/Hib/HepB vaccine ordering

Supplies of DTaP/IPV/Hib/HepB vaccines Infanrix hexa® and Vaxelis® are available for the routine infant primary immunisations programme.

Orders for Infanrix hexa® remain unrestricted. Customers in England and Wales may order up to 20 packs of Vaxelis® per ImmForm account per week. Customers in Scotland should refer to their local ordering restrictions. Providers should not order more than 2 weeks’ worth of stock to minimise wastage due to fridge failures.  For assistance, please contact helpdesk@immform.org.uk.

The EU Falsified Medicines Directive and Delegated Regulation as applicable to UKHSA-supplied vaccines for the national immunisation programme

The EU Falsified Medicines Directive 2011/62/EU (FMD) and Delegated Regulation ((EU) 2016/161) (the Delegated Regulation) impose legal obligations on the EU medicines supply chain to prevent entry of falsified medicinal products into the supply chain. The Delegated Regulation was implemented in all EU Member States on 9 February 2019. Following the UK’s departure from the EU, the Delegated Regulation ceased to apply in Great Britain from 31 December 2020, but continues to apply in Northern Ireland.

Information for customers in Northern Ireland

FMD-barcoded packs of routine immunisation programme vaccines that are centrally supplied by UKHSA continue to be supplied with active FMD serialisation, and should be decommissioned by end users in Northern Ireland. Customers in Northern Ireland who access centrally supplied vaccines are encouraged to review local guidance on implementation of the FMD.

MMR vaccine ordering

To rebalance central supplies of both MMR vaccines, please consider ordering M-M-RvaxPRO® as your first choice, which is available to all customers without restriction.

Customers in England and Wales who require Priorix®, for example because you serve communities that do not accept vaccines containing porcine gelatine, may order up to 12 packs of Priorix® per ImmForm account per week. For assistance with ordering more than 12 packs of Priorix®, please email your request to helpdesk@immform.org.uk.   

Customers in Scotland should refer to their local ordering restrictions.

Non-routine vaccine supply

Hepatitis A vaccine                   

Adult:

• GSK: supply of Havrix Adult PFS singles and packs of 10 are currently available
• Sanofi: Avaxim PFS singles are currently available (Avaxim packs of 10 are currently available)
• MSD: VAQTA Adult is available         

Paediatric:                       

• GSK: supply of Havrix Paediatric singles and packs of 10 are currently available
• MSD: VAQTA Paediatric is available
• Sanofi: Avaxim Junior singles are currently available

Hepatitis B vaccine                             

Adult:                     

• GSK: Engerix B PFS singles and packs of 10 are currently available
• GSK: supply of Fendrix is currently available
• MSD: HBVAXPRO 10µg is available
• MSD: HBVAXPRO 40µg is available
• Valneva: PreHevbri is available

Paediatric:                        

• GSK: supplies of Engerix B Paediatric singles are currently available
• MSD: HBVAXPRO 5µg is available

Combined hepatitis A and B vaccine                      

• GSK: Twinrix Adult singles and packs of 10 are available
• GSK: Twinrix Paediatric is currently available
• GSK: Ambirix is available

Combined hepatitis A and typhoid vaccine                      

Sanofi: Viatim is now a discontinued product and no longer available for sale

Typhoid vaccine             

• Sanofi: Typhim singles and packs of 10 are available
• Patientric: Vivotif is available

Rabies vaccine                         

• Valneva: Rabipur is currently available
• Sanofi: Verorab is currently available

Pneumococcal polysaccharide vaccine (PPV)                 

MSD: supply of Pneumovax 23 (PPV23) PFS is available                                   

Pneumococcal polysaccharide conjugate vaccine (PCV)           

• Pfizer: Prevenar 13 is currently available
• MSD: Vaxneuvance is currently available

Varicella zoster vaccine                      

• GSK: VARILRIX is currently available
• MSD: VARIVAX is available.
• MSD: ZOSTAVAX is a discontinued product

Diphtheria, tetanus and poliomyelitis (inactivated) vaccine                           

Sanofi: Revaxis is available                                                 

Diphtheria, tetanus, pertussis (acellular) and poliomyelitis (inactivated) vaccine

• GSK: supply of Boostrix-IPV is currently available
• Sanofi: Repevax is currently available

MMR                     

• MSD: MMR Vaxpro is currently available
• GSK: Priorix is currently available

Meningitis ACWY vaccine                             

• GSK: Menveo is currently available
• Pfizer: Nimenrix is currently available
• Sanofi: MenQuadfi is available

Yellow fever          

Sanofi: Stamaril is available        

Human papillomavirus vaccine  

• MSD: GARDASIL has been discontinued
• MSD: Gardasil 9 is currently available
• GSK: Cervarix has been discontinued

Cholera vaccine                        

• Valneva: Dukoral is available
• Patientric: Vaxchora is available

Japanese encephalytis vaccine                    

Valneva: Ixiaro is available                    

Meningococcal group B vaccine

GSK: Bexsero is currently available       

Diphtheria, tetanus, pertussis, Hib vaccine and poliomyelitis

GSK: Infanrix IPV+Hib is currently available

Hib and meningococcal group C combined vaccine

GSK: Menitorix is currently available                

Live attenuated rotavirus vaccine

GSK: Rotarix is currently available                   

Herpes zoster vaccine    

GSK: Shingrix is currently available

Diphtheria, tetanus and pertussis

Sanofi: Adacel is available to order without restrictions         

Dengue tetravalent vaccine

Takeda: Qdenga is currently available

Respiratory syncytial virus vaccine

Pfizer: Abrysvo is currently available